Metraipolis › archive › dc_134d44636299
Anti-α-synuclein drug — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/Anti-%CE%B1-synuclein_drug
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-09T14:20:13.462Z
- SHA-256 of the archived text
5bd2a6c635051a8a524f75d4bf74982ece97416cb5cfe73c946a0189991c14a6- Stable URL of this page
https://metraipolis.com/documento/dc_134d44636299
How to cite
Anti-α-synuclein drug — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Anti-%CE%B1-synuclein_drug (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_134d44636299 (Metraipolis archive dc_134d44636299, sha256 5bd2a6c635051a8a524f75d4bf74982ece97416cb5cfe73c946a0189991c14a6)
BibTeX
@misc{dc134d44636299,
title = {Anti-α-synuclein drug — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/Anti-%CE%B1-synuclein_drug},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_134d44636299; sha256 5bd2a6c635051a8a524f75d4bf74982ece97416cb5cfe73c946a0189991c14a6},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Anti-%CE%B1-synuclein_drug. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
An anti-α-synuclein drug, or an α-synuclein inhibitor, is a drug which blocks or inhibits α-synuclein. α-Synuclein is a protein which is thought to be involved in the development and progression of α-synucleinopathies including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Anti-α-synuclein drugs are under development for treatment of Parkinson's disease and other α-synuclein-related diseases. Examples include the monoclonal antibodies prasinezumab and cinpanemab, which both failed to show effectiveness in slowing the progression of Parkinson's disease in phase 2 clinical trials. Other anti-α-synuclein drugs, like the monoclonal antibodies exidavnemab and amlenetug, the α-synuclein vaccines PD01A and PD03A, and the small-molecule α-synuclein misfolding and aggregation inhibitors minzasolmin and emrusolmin, are also under development. Memantine is also being studied as a potential disease-modifying treatment for Parkinson's disease by inhibiting cell-to-cell transmission of α-synuclein and is in a phase 3 trial for this purpose. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «Anti-α-synuclein drug» — https://en.wikipedia.org/wiki/Anti-%CE%B1-synuclein_drug Wikidata Q130485030: «drugs that inhibit α-synuclein» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q130485030 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Anti-%CE%B1-synuclein_drug?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1364893211, consultata il 2026-11-09T14:16:38.424Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: e3b45491c705281280472224dc674cfb2d87951a11e289afbea180c9c86b0d37